Melanotan II: The Complete Research Profile (2026)

MT-II's full effect profile only makes sense once you understand that it does not selectively target skin. The melanocortin system is a family of five G-protein-coupled receptors (MC1R–MC5R), each expressed in different tissue and each driving a distinct physiological output. MT-II is a broad-spectrum agonist that activates all five, with varying affinity — this non-selectivity is the central pharmacological fact that explains both its cosmetic tanning effect and its side-effect burden.

MT-II's tanning effect proceeds through a well-characterised intracellular signalling cascade. MT-II binds MC1R on the surface of epidermal melanocytes, activating adenylyl cyclase and raising intracellular cAMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB. Phosphorylated CREB drives transcription of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte gene expression. MITF activation upregulates tyrosinase, TRP-1, and TRP-2 — the enzymatic machinery required to synthesise melanin — shifting output toward eumelanin (brown-black pigment) rather than pheomelanin (red-yellow pigment).

The net effect is skin darkening via increased eumelanin content, achievable without significant UV exposure. In the foundational human studies, visible pigmentation change was reported after 5–7 days of daily dosing, with maximum pigmentation typically reached at 3–4 weeks (Dorr et al. 2000).

Because MT-II is non-selective, activation of receptors beyond MC1R produces effects unrelated to pigmentation:

• MC3R / MC4R (hypothalamus): decreased appetite — weight loss was observed as a secondary finding in some early trials — and increased sexual arousal, including spontaneous erections reported in male trial participants without sexual stimulation (Wessells et al., Urology 2000).
• MC5R (exocrine glands): increased sebum production and facial flushing.
• Autonomic signature: dose-dependent nausea that typically subsides after the first several doses, plus a distinctive yawning/stretching syndrome reported consistently across trials and case series.

Melanotan I (afamelanotide) is the linear α-MSH analog — the compound behind the EMA- and FDA-approved drug Scenesse, indicated for erythropoietic protoporphyria (EPP) to increase pain-free light exposure (FDA Scenesse label). MT-I has considerably cleaner MC1R selectivity, giving it a better tanning-to-side-effect ratio, but it requires a slow-release subcutaneous implant administered by a clinician roughly every two months. MT-II is the cyclic, lactam-bridged analog — faster-acting and effective at lower cumulative doses, but with broader receptor activity across MC1R, MC3R, MC4R and MC5R, which brings a correspondingly larger side-effect footprint.

Protocols reported in the literature and research-community sources generally describe a two-phase structure:

• Loading phase: 250–500 mcg subcutaneous daily until desired pigmentation is reached, typically 1–3 weeks.
• Maintenance phase: 250–500 mcg, 1–2 times per week, with total cumulative exposure kept as low as practical to reduce cumulative MC5R/MC4R-driven side effects.
• Timing: administration on an empty stomach or with a light meal is commonly reported to reduce the severity of nausea.
• Intranasal route: nasal spray administration has been studied at roughly 3–4× the subcutaneous dose to achieve comparable systemic exposure, reflecting lower bioavailability by that route.

These figures describe protocols reported in the literature and research-community sources; they are not clinical dosing recommendations, and no regulatory body has established a safe or effective human dose for MT-II.

The human evidence base for MT-II is comparatively substantial for a research peptide but falls well short of a therapeutic drug's evidentiary standard. It consists of extensive preclinical (rodent and in-vitro) work, several small Phase I-style pilot studies in healthy volunteers, and a handful of controlled crossover trials in the erectile-function context — but no Phase 3 trial for the tanning indication was ever completed, and MT-II development for cosmetic tanning was ultimately abandoned in favour of its more selective successor, PT-141.

Beyond the melanocytic signal, the documented safety profile includes:

• Melanocytic nevus changes: darkening of existing moles and potential new nevus development, reported even after short-term use (Cardones & Grichnik 2009).
• Melanoma case reports: multiple published cases describe melanoma or melanoma in situ arising in nevi that changed during MT-II use (Langan et al. 2010). No prospective controlled trial has quantified lifetime cancer risk.
• Nausea, flushing, spontaneous erections: common, expected, and generally the dose-limiting effects in formal trials.
• Non-uniform hyperpigmentation: existing freckles and macules can darken disproportionately relative to surrounding skin.
• Rare systemic toxicity — rhabdomyolysis: a documented emergency case involved sympathomimetic toxicity and rhabdomyolysis following a supratherapeutic 6 mg subcutaneous dose, with creatine phosphokinase peaking at 17,773 IU/L (Nelson, Bryant & Aks, Clinical Toxicology 2012; referenced in the case-report literature alongside Ong et al. case series on melanotan-associated toxicity).

This is meant as an honest research risk profile, not a marketing summary. Anyone considering MT-II research protocols should weigh these signals seriously, particularly the dermatological ones, which are the most consistently reported serious concern in the literature (BMJ 2009).

MT-II is typically supplied as a lyophilised powder in a 10 mg vial. Standard reconstitution uses bacteriostatic (BAC) water — 2 mL of BAC water yields a concentration of approximately 5 mg/mL. Subcutaneous injection is the preferred research route. Reconstituted peptide should be kept refrigerated (2–8°C) and protected from light, and injection sites should be rotated to reduce local irritation and lipohypertrophy risk over repeated dosing.

Given the dermatological safety signal, a baseline dermatology mole map is essential before starting any MT-II research protocol — not optional. Alongside this, baseline blood pressure, a lipid panel, and a full blood count (CBC) provide useful reference points given the cardiovascular and systemic signals reported in the toxicity case-report literature. Mole mapping should be repeated every 3–6 months for the duration of use and for a period afterward. A dermatology consult prior to starting any MT-II research protocol is standard practice, particularly for individuals with a personal or family history of melanoma, dysplastic nevi, or high nevus counts.

For a full walkthrough of which biomarkers matter and how to read them, see the Bioactive Compounds bloodwork guide.

Melanotan II is available as a 10 mg vial through Bioactive Compounds. It is not currently on our published price list, so pricing is shown as From £45 — final quotes are confirmed directly via WhatsApp. For researchers specifically interested in the sexual-arousal mechanism without the broader MC1R/MC5R activity, the MC4R-selective successor compound, PT-141 (bremelanotide), is worth reviewing as a cleaner alternative — see the pen builder for current PT-141 protocol options.